HMGB1 and graft versus host disease: More directly, cyclopentylamino carboxymethylthiazolylindole (NecroX)-7 has attenuated acute GVHD by inhibiting the formation of mitochondria specific ROS/reactive nitrogen species, in turn, preventing the release of High-mobility group box 1 (HMGB1) (23).